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AbstrACt
Introduction Paget’s disease of bone (PDB) is 
characterised by increased and disorganised bone 
remodelling affecting one or more skeletal sites. 
Complications include bone pain, deformity, deafness 
and pathological fractures. Mutations in sequestosome-1 
(SQSTM1) are strongly associated with the development 
of PDB. Bisphosphonate therapy can improve bone pain 
in PDB, but there is no evidence that treatment alters 
the natural history of PDB or prevents complications. 
The Zoledronate in the Prevention of Paget’s disease 
trial (ZiPP) will determine if prophylactic therapy with the 
bisphosphonate zoledronic acid (ZA) can delay or prevent 
the development of PDB in people who carry SQSTM1 
mutations.
Methods and analysis People with a family history 
of PDB aged >30 years who test positive for SQSTM1 
mutations are eligible to take part. At the baseline visit, 
participants will be screened for the presence of bone 
lesions by radionuclide bone scan. Biochemical markers 
of bone turnover will be measured and questionnaires 
completed to assess pain, health-related quality of life 
(HRQoL), anxiety and depression. Participants will be 
randomised to receive a single intravenous infusion of 
5 mg ZA or placebo and followed up annually for between 
4 and 8 years at which point baseline assessments will be 
repeated. The primary endpoint will be new bone lesions 
assessed by radionuclide bone scan. Secondary endpoints 
will include changes in biochemical markers of bone 
turnover, pain, HRQoL, anxiety, depression and PDB-related 
skeletal events.
Ethics and dissemination The study was approved by 
the Fife and Forth Valley Research Ethics Committee on 
22 December 2008 (08/S0501/84). Following completion 
of the trial, a manuscript will be submitted to a peer-
reviewed journal. The results of this trial will inform clinical 
practice by determining if early intervention with ZA in 
presymptomatic individuals with SQSTM1 mutations can 
prevent or slow the development of bone lesions with an 
adverse event profile that is acceptable.
trial registration number ISRCTN11616770
strengths and limitations of this study
 ► This is the first randomised placebo-controlled trial 
to test whether genetic testing coupled with target-
ed intervention with zoledronic acid can modify the 
development and progression of bone lesions sec-
ondary to Paget’s disease.
 ► The inclusion of individuals with sequestosome-1 
mutations ensures that participants have a high risk 
of developing Paget’s disease and provides a suit-
able cohort in which to study the potential benefit of 
prophylactic treatment.
 ► The choice of zoledronic acid maximises the likeli-
hood of preventing the development of bone lesions 
in this high-risk population.
 ► The randomised double-blind placebo-controlled 
design of the trial reduces the risk of selection and 
assessment bias.
 ► The study duration is unlikely to be sufficient to eval-
uate the effect of the intervention on complications 
of Paget’s disease such as bone pain, deformity and 
pathological fractures. Longer periods of follow-up 
of this cohort will be required.
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box 1 Outcome measures for the Zoledronate in the 
Prevention of Paget’s disease trial
Primary
 ► The total number of subjects who develop new bone lesions on ra-
dionuclide bone scans with the characteristics of Paget’s disease of 
bone (PDB) between the baseline visit and the final follow-up visit.
secondary
 ► The number of new bone lesions on radionuclide bone scan.
 ► Change in activity of existing bone lesions that were present at the 
baseline assessed by semiquantitative analysis of radionuclide bone 
scans.28
 ► The development of PDB-related skeletal events defined as any one 
of the following:
Development of new bone lesions thought to be due to PDB on 
imaging.
Development of complications thought to be due to the develop-
ment or progression of PDB including pathological fractures, bone 
deformity, deafness, joint replacement surgery or other orthopaedic 
procedures.
Administration of treatment for PDB with an antiresorptive drug be-
cause of the development of signs or symptoms thought to be due 
to PDB such as pain localised to an affected site or neurological 
symptoms.
 ► The development of increased bone turnover as assessed by mea-
surement of biochemical markers of bone resorption and bone 
formation.
 ► Quality of life, anxiety and depression assessed by the Short Form 
(36) Health Survey, Brief Pain Inventory (BPI) and Hospital Anxiety 
and Depression Questionnaire.
 ► Location, presence and severity of pain assessed by the BPI manikin 
and pain questionnaire.
bACkgrOund
Paget’s disease of bone (PDB) is characterised by areas of 
increased and disorganised bone turnover affecting one 
or more skeletal sites. Many affected individuals develop 
complications such as bone pain, deformity, deafness, 
pathological fracture and osteoarthritis. Genetic factors 
play an important role in PDB. Many genetic variants 
have been identified that predispose to PDB and related 
syndromes1 2 but mutations in sequestosome-1 (SQSTM1) 
are the most important predisposing factor, occurring in 
up to 50% of patients with a family history of PDB and 
up to 10% of people who are unaware of having a family 
history.3–8 Carriers of SQSTM1 mutations have more severe 
disease with an earlier age at onset than patients who do 
not carry mutations.9 Cross-sectional studies indicate that 
the penetrance of PDB in SQSTM1 mutation carriers is 
about 80% above the age of 70 years.10 However, there 
has been only one prospective study of disease evolution 
in mutation carriers. This study involved 10 families with 
SQSTM1 mutations. Four out of 23 (17%) mutation carriers 
had developed the PDB disease by the age of 50 as assessed 
by radionuclide bone scanning, but the age at diagnosis 
was delayed compared with their parents’ age.11 Bisphos-
phonates are considered to be the treatment of choice 
for PDB, and within the bisphosphonates, zoledronic acid 
(ZA) is most likely to give a favourable response in terms of 
bone pain.12 ZA has a long duration of action in patients 
with established PDB with inhibitory effects on bone turn-
over that are superior to those of risedronate. 13 The main 
indication for bisphosphonate treatment in PDB is bone 
pain thought to be due to increased metabolic activity of 
the disease.12 14 Although bisphosphonates are highly effec-
tive at suppressing elevated bone turnover in PDB, there 
is no evidence that giving bisphosphonate treatment with 
the primary aim of suppressing elevated bone turnover is of 
clinical benefit.14 There is also no evidence that treatment 
can prevent complications of PDB such as fracture, bone 
deformity, deafness or secondary osteoarthritis.14 15 16 The 
Zoledronate in the Prevention of Paget’s disease (ZiPP) 
trial has been designed to determine if prophylactic treat-
ment with ZA is effective at preventing the development or 
progression of bone lesions with the characteristic features 
of PDB in asymptomatic SQSTM1 mutation carriers. The 
reason for choosing people with SQSTM1 mutations is that 
these are relatively common in PDB and because carriers of 
SQSTM1 mutations have a high risk of developing PDB with 
increasing age.
good clinical practice
The study will be carried out according to the princi-
ples of the International Conference on Harmonisation 
Tripartite Guideline for Good Clinical Practice and local 
guidance and regulations
Consolidated standards of reporting trials
The results of the trial will be reported in accordance 
with the Consolidated Standards Of Reporting Trials 
statement.
Aim
To improve clinical outcome in PDB by exploring 
whether genetic testing for SQSTM1 mutations coupled 
with prophylactic treatment with ZA, can prevent or 
delay the development of bone lesions, prevent skeletal 
complications and favourably modify pain and quality of 
life in those genetically at risk because of a positive family 
history.
Objectives
The study objectives are summarised in box 1 and 
described in more detail below:
Primary objective:
To quantify the number of subjects in each treatment 
group who develop new bone lesions with the charac-
teristics of PDB as assessed by radionuclide bone scan. 
The presence and location of lesions will be assessed by 
imaging experts blinded to treatment allocation. A new 
bone lesion will be defined as evidence of involvement 
of a new bone or part of a previously affected bone at the 
end-of-study visit which was not thought to be involved at 
the baseline visit.
Secondary objectives:
To quantify the number of new bone lesions and change 
in activity of existing bone lesions present at baseline; to 
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Table 1 Summary of assessments and outcome measures for the ZiPP trial
Screening Baseline visit +1 week Annual review End of study
Medical history ✓ ✓ ✓
Current medication ✓ ✓ ✓
Physical examination ✓
Height, weight, blood pressure ✓ ✓
Routine biochemistry* ✓ ✓ ✓ ✓
Haematology† ✓ ✓
Blood for biomarkers‡ ✓ ✓
Urine for biomarkers§ ✓ ✓
SQSTM1 genotyping ✓
25(OH) vitamin D ✓
Pregnancy test¶ (in women of childbearing 
potential)
✓
Radionuclide bone scan ✓ ✓
Radiographs or other imaging** ✓ ✓
Infusion ✓
Telephone Questionnaire ✓
Food Frequency Questionnaire ✓
SF-36, HADS and BPI questionnaires ✓ ✓ ✓
PDB-related skeletal events ✓
*Calcium, albumin/total protein, alkaline phosphatase, liver function (AST, ALT, GGT, bilirubin), urea and electrolytes and creatinine.
†Full blood count.
‡Blood samples for measurement of bone-specific alkaline phosphatase, PINP, CTX-I and other specialised markers of bone metabolism.
§Second-voided morning urine to be taken and stored for measurement of N-telopeptide collagen cross links, deoxypyridinoline/creatinine 
ratio and other specialised markers of bone metabolism.
¶A negative pregnancy test must be obtained on the day of, or the day before, infusion of the study drug. The preferred method of is serum 
beta-hCG, but a urine beta-hCG is acceptable for centres that are unable to obtain a serum beta-hCG.
**To be taken of relevant areas in subjects suspected to have PDB-like bone lesions on bone scan.
ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; BPI, Brief Pain Inventory; CTX-I, C-terminal telopeptide of type I collagen; 
GGT, Gamma glutamyl transferase; HADS, Hospital Anxiety and Depression Questionnaire; hCG, Human chorionic gonadotrophin; 
PDB, Paget’s disease of bone; PINP, N-terminal propeptide of type I procollagen; SF-36, Short Form (36) Health Survey ; SQSTM1, 
sequestosome-1; ZiPP, Zoledronic acid in the Prevention of Paget’s disease.
evaluate the effects of treatment on skeletal events related 
to PDB; to evaluate the effects of treatment on biochem-
ical markers of bone resorption and bone formation and 
to evaluate the effects of treatment on health-related 
quality of life (HRQoL), anxiety and depression and the 
presence, localisation and severity of pain.
Outcome measures
The schedule of assessments and outcome measures, 
which will be collected during the study, are summarised 
in table 1 and are discussed individually in more detail 
below.
Bone lesions
These will be assessed by Tc99 radionuclide bone scan, 
which is recognised to be the most sensitive imaging 
technique for identifying bone lesions in PDB.14 17 Partic-
ipants thought to have PDB-like bone lesions on scan may 
have further imaging performed by X-ray, CT scan or MRI 
scan if the local investigator considers it clinically indi-
cated. Anonymised bone scan and X-ray images will be 
uploaded on to the study database for review. All scans will 
be reviewed by an imaging expert blinded to treatment 
allocation. A proportion of images will be reviewed by a 
second imaging expert, also blinded to treatment alloca-
tion, to evaluate concordance between the observers. The 
images selected will include all of those considered by the 
primary imaging expert to represent PDB-like lesions. In 
the event that the experts disagree on a specific image, a 
third imaging expert (also blinded to treatment alloca-
tion) will be asked to adjudicate.
Clinical assessments
Participants will undergo a physical examination at the 
baseline visit including blood pressure and pulse. Partic-
ipants will be evaluated clinically at the end-of-trial visit 
4 Cronin O, et al. BMJ Open 2019;9:e030689. doi:10.1136/bmjopen-2019-030689
Open access 
for any symptoms or signs of skeletal events thought to be 
related to PDB.
Biochemical markers
Measurements of serum creatinine, urea and electrolytes, 
serum total alkaline phosphatase (ALP), serum calcium, 
albumin and liver function tests which will consist of 
aspartate aminotransferase (AST) alanine aminotrans-
ferase (ALT), gamma glutamyl transferase (GGT) and 
bilirubin along with a full blood count will be performed 
using standard techniques at the local laboratories in 
participating centres. Estimated glomerular filtration 
rate (GFR) will be calculated from serum creatinine, 
gender and weight by the Cockcroft-Gault equation. 18 
Specialised biochemical markers of bone turnover will 
be measured centrally at the University of East Anglia. 
These will include urine N-telopeptide collagen cross 
links (NTX) corrected for urinary creatinine; C-terminal 
telopeptide of type I collagen (CTX-I), bone-specific alka-
line phosphatase (BSAP) and the N-terminal propeptide 
of type I procollagen (PINP). These measurements will 
be made on fasting samples collected between 09:00 and 
12:00 hours as previous studies have shown that markers 
of bone resorption have a circadian rhythm and are influ-
enced by food intake.19 The urine samples will be second-
voided ‘spot’ samples collected after an overnight fast. 
The preferred markers of bone resorption are urinary 
NTX and serum CTX-I. These have been found to be 
elevated in patients with PDB in case–control studies 14 
and to correlate with the extent of bone lesions as deter-
mined by scintigraphy in PDB.20 The preferred markers 
of bone formation will be PINP and BSAP since both have 
been shown to be superior to total ALP at detecting PDB 
in case–control studies.14 Additional biomarkers of bone 
metabolism may also be assessed if new information indi-
cates that these may be of interest as the study progresses. 
The serum, plasma and urine samples will be aliquoted 
and stored locally at −80°C and shipped on dry ice to the 
central laboratory.
Health-related quality of life
HRQoL will be assessed by completion of the Short Form 
(36) Health Survey (SF-36) questionnaire21 at baseline, 
annual visits and the end-of-study visit. The SF-36 is a 
widely used, validated questionnaire21 previously used to 
assess quality of life in patients with established PDB.15 16
Pain
The presence and location of pain will be assessed by 
completion of the Brief Pain Inventory (BPI)22 at base-
line, annual visits and the end-of-study visit. The BPI was 
originally developed to evaluate the location and severity 
of pain in patients with malignant disease but has since 
been validated in people with chronic non-malignant 
pain.23 In addition to completing BPI, participants will 
also be asked if they have experienced any pain and bone 
pain
Anxiety and depression
Anxiety and depression will be assessed by the Hospital 
Anxiety and Depression Questionnaire (HADS).24 This 
questionnaire was chosen since it is quick and simple to 
administer and has it has been extensively validated in 
many different countries and settings.25
Paget’s disease-related skeletal events
Participants will be evaluated clinically at the end of study 
for the presence of Paget’s disease-related skeletal events 
(PDRSE). These will include pathological fractures, bone 
deformity, deafness due to skull involvement, and joint 
replacement surgery or other surgical procedures that 
are a carried out because of PDB. Administration of an 
antiresorptive drug during the study because of signs 
or symptoms that are thought to be due to PDB will be 
considered as a PDRSE as will the development of new 
bone lesions on bone scan. All events will be combined 
for each treatment group to give a total score.
Genetic testing
Genetic testing will be conducted to determine eligibility 
by Sanger sequencing of exons 7 and 8 of SQSTM1 and 
the intron–exon boundaries using DNA extracted from a 
venous blood sample according to standard techniques.9
sample size
The sample size was chosen assuming that 15% of patients 
in the placebo group and 1.5% of patients in the active 
(ZA) treatment group will develop new PDB-like bone 
lesions during follow-up. This was based on the observa-
tion that ZA has been reported to normalise biochemical 
markers of bone turnover for up to 6.5 years in 90% of 
patients with established PDB.26 With this assumption, 
85 subjects in each group would provide 89% power to 
detect a treatment effect of this magnitude at an alpha 
of 0.05. Since it is possible that more than one affected 
subject per family could be enrolled, the sample size was 
inflated to account for relatedness of individuals. This 
was done by calculating the mean squared alkaline phos-
phatase values in patients within families who carried 
the same mutation (271.3) and the mean squared alka-
line phosphatase values between families (619.7) and 
combining this with the estimated average number of 
two subjects per family who may be enrolled in the study. 
This resulted in a design effect factor of 1.39, inflating 
the required sample size to 118 per group. In addition to 
this, the sample size was further inflated to account for 
a 10% rate of participants lost to follow-up resulting in a 
total sample size of 130 subjects per group or 260 subjects 
in total. The actual number of subjects randomised to the 
interventional study by the time recruitment had closed 
in April 2015 was 222 and to the observational study 
was 135. The decision to stop recruitment was based on 
funding, and justified by recalculating the design factor 
based on the actual number of subjects per family that 
had been enrolled into the study (1.5 on average). The 
design factor was recalculated to be 1.26.
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box 2 Eligibility and exclusion criteria for the Zoledronate 
in the Prevention of Paget’s disease trial
Eligibility criteria
 ► Carrier of sequestosome-1 mutation.
 ► Aged 30 years or older.
 ► Not already diagnosed with Paget’s disease of bone (PDB).
Exclusion criteria
 ► Already diagnosed with PDB.
 ► Unwilling or unable to provide informed consent.
 ► Contraindication to bisphosphonates.
 ► Estimated GFR <35 mL/min.
 ► Hypocalcaemia.
 ► Receiving bisphosphonate therapy for another reason.
 ► Osteonecrosis of the jaw.
 ► Metastatic cancer or cancer diagnosed less than 2 years ago where 
treatment is still ongoing.
 ► Active uveitis, iritis or episcleritis.
 ► Already taking part in another randomised controlled clinical trial.
 ► Pregnancy or lactation at the time of randomisation or bone 
scanning.
Figure 1 Genetic testing phase of the ZiPP study for probands the figure provides an overview of the process and procedures 
for genetic testing of probands and contact of family members. PDB, Paget’s disease of bone; PRISM, Paget's Disease: 
Randomised Trial of Intensive versus Symptomatic Management; SQSTM1, sequestosome-1; ZIPP, Zoledronic acid in the 
Prevention of Paget’s disease.
Methodology
Eligibility
Those eligible will be 30 years of age or older, with a posi-
tive family history of PDB, in whom genetic testing had 
shown a pathogenic mutation in SQSTM1. Individuals 
who had already been diagnosed with PDB prior to the 
baseline visit will be excluded, as will those with contra-
indications to ZA as summarised in box 2. In order to 
identify people who may be eligible for participation, 
an extensive programme of genetic testing of probands 
for SQSTM1 mutations will be carried out. An overview 
of this process is summarised in figure 1. Patients with a 
diagnosis of PDB (probands) identified through various 
sources will be contacted by letter and asked if they 
would like to be tested for the presence of mutations in 
the SQSTM1 gene. Those that test negative for SQSTM1 
mutations will be informed of the result and counselled 
but they and their family members excluded from further 
involvement in the study. Those that tested positive will be 
informed of the result, counselled about the implications 
and asked to pass an information pack about the trial 
onto any eligible blood relatives with a reply slip that can 
be returned to the local recruiting centre. Subsequently, 
a programme of genetic testing for SQSTM1 mutations 
will be conducted on relatives to identify individuals who 
may be eligible to take part in the trial. The results of 
this process are summarised in figure 2. Participants with 
serum 25(OH) vitamin D levels below the lower limit of 
the local reference range will be permitted to take part 
in the trial but only after they had been treated with 
vitamin D supplements in order to mitigate the risk of 
hypocalcaemia following ZA treatment. Recruitment into 
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Figure 2 Genetic testing phase for relatives and subsequent enrolment to the ZiPP study. The figure provides an overview 
of the process and procedures for genetic testing of relatives as well as an outline of the flow of subjects who consented 
to participate in the intervention and observational studies. PRISM, Paget's Disease: Randomised Trial of Intensive versus 
Symptomatic Management; SQSTM1, sequestosome-1; ZiPP, Zoledronic acid in the Prevention of Paget’s disease.
the clinical trial will be delayed in participants who are 
scheduled to have dental surgery (tooth extractions, root 
treatment or other surgery to the mandible or maxilla), 
until healing had occurred to mitigate the risk of osteone-
crosis of the jaw. Likewise, if the potential participant has 
dental surgery planned within the first 3 months of the 
expected infusion date, their recruitment will be delayed 
until healing is complete. Minor dental procedures such 
as descaling and fillings will not constitute a barrier to 
enrolment. Participants in Ireland will be required to 
undergo a dental examination within 1 month prior to 
the baseline visit at the request of Health Products Regu-
latory Authority in Ireland. Women who are pregnant or 
breast feeding will be excluded. Women of childbearing 
potential will be permitted to take part provided that 
they agreed to practise a medically robust form of contra-
ception before and for at least 12 months after the ZA 
infusion (an intrauterine device, a barrier method with 
spermicide, condoms, subdermal implant or oral contra-
ceptive). In the event that a woman becomes pregnant or 
is lactating during the study, bone scanning and X-rays 
will not be performed until the patient is no longer preg-
nant and has ceased lactating.
Observational study
During the genetic testing phase, we identified 400 indi-
viduals who tested negative for SQSTM1 mutations and 
135 (33.7%) agreed to enrol into an observational study. 
Participants in the observational study will have HRQoL 
and anxiety and depression measures assessed by comple-
tion of the SF-36 and HADS questionnaires at the base-
line and end-of-study visits. They also will have samples 
for routine biochemistry checked at baseline and the 
end-of-study visit and will have samples stored for assess-
ment of biochemical markers of bone turnover.
Consent
The consent process will be divided into three stages. The 
first phase will involve obtaining consent from patients 
with PDB (probands). The second phase will involve 
obtaining consent from relatives probands for genetic 
testing. Although the relatives will be made aware of the 
trial, the consent will be obtained only for genetic testing, 
without any commitment to enter the trial. The third 
phase will involve obtaining consent for entry into the 
trial or observational study.
Randomisation
Randomisation will be performed by a web-based tool 
hosted by Edinburgh Clinical Trials Unit, to ensure allo-
cation concealment prior to enrolment. The randomisa-
tion algorithm will employ minimisation to ensure that 
the groups are balanced for prognostic variables thought 
to influence the occurrence of PDB including: the type of 
mutation (missense vs truncating or frameshift); gender; 
whether the baseline radionuclide bone scan shows 
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lesions suggestive of PDB; whether serum total alkaline 
phosphatase levels at baseline are elevated (yes/no); and 
by age band: 30–40, 41–50, 51–60, 61–70 and 71 or over. 
Following randomisation, the study database will generate 
a treatment code which will be used by the research phar-
macies in each participating centre to ensure that the 
correct medication is dispensed.
Prerandomisation and postrandomisation withdrawals
Participants will be advised that they have the right to 
withdraw from the study at any time for any reason. The 
investigator will have the right to withdraw a participant 
at any time if it is deemed to be in the participant’s best 
interest. If a participant decides that they no longer wish to 
continue with routine assessments or adhere to the study 
protocol before the planned end-of-trial assessment, they 
will be given the opportunity to attend for the end-of-trial 
assessment. The same will apply to participants in whom 
the local investigator decides that adherence to the trial 
protocol would be inappropriate.
Blinding
The participants and investigators will be blinded to 
treatment allocation. The ZA and placebo infusions will 
be identical. Breaking the blind will only be performed 
where knowledge of the treatment is absolutely necessary 
for further management of the patient and can only be 
performed by contacting the local pharmacy, which will 
have restricted code break details.
Interventions
The investigational medicinal product (IMP), ZA 
(Aclasta, Novartis Pharmaceuticals UK, Surrey, UK), has 
been widely used in the treatment of both osteoporosis 
and PDB.12 13 The most common side effects are tran-
sient influenza-like symptoms occurring in up to 50% of 
patients although these are usually mild.27 The IMP will 
be given by intravenous infusion and will comprise ZA 
(5 mg in 100 mL ready-to-infuse solution) or a matching 
placebo. Both will be given at a constant infusion rate 
over not less than 15 min. Medications required for the 
participants’ clinical care will be permitted during the 
study. Should a participant require treatment with a bone 
active antiresorptive medication (such as a bisphospho-
nate, strontium ranelate or denosumab) after randomisa-
tion but prior to infusion of the IMP, then the participant 
will not receive the study IMP but will still be followed up 
as per protocol. Female patients of childbearing poten-
tial will be required to have a negative pregnancy test on 
the day of, or the day before, infusions of the study drug. 
Participants who are sexually active will receive specific 
advice about the possible risks associated with getting 
pregnant while in the trial and will be asked to agree to 
practise a medically acceptable form of birth control for 
at least 12 months postinfusion of IMP. Female partici-
pants who inadvertently become pregnant during the 
trial will be excluded from isotope bone scanning during 
pregnancy or breast feeding.
data management
Paper case record forms (CRF) will be provided to record 
baseline and follow-up clinical measurements and demo-
graphics by local research teams. Data from these CRF 
will then be entered onto a web-based electronic CRF. 
The principal investigator (PI) at each study site will be 
responsible for the quality of the data recorded in the 
CRF. The ZiPP study eCRF web portal will be built and 
maintained by the software development team of the 
University of Edinburgh’s Clinical Trials Unit, following 
internal standard operating procedures. A Microsoft 
stack will be used. The back-end repository will be a MS 
SQL-Server. The front-end user interface will be imple-
mented using ASP.Net technologies.
Adverse event management
Participants will be provided with an event diary to record 
details of primary care visits, medications taken, hospital-
isations and any other adverse effects or health problems. 
In the event of hospitalisation, the patient will be asked to 
contact the PI at their local study centre. Adverse events 
(AE), serious AEs (SAE) and suspected unexpected serious 
adverse reactions (SUSAR) will be collected continuously 
throughout the trial. In addition, participants will be 
contacted by local research teams 1 week after receipt of 
the infusion to record symptoms or side effects related to 
this intervention. All AEs will be recorded from the time 
a participant consents to join the study until the last study 
visit has been completed. The investigator or a delegated 
member of the study team will record AEs at every visit 
and participants will be instructed to contact the inves-
tigator at any time if AEs develop. If an AE/SAE occurs, 
it is the responsibility of the investigator to review all the 
documentation related to the event and evaluate serious-
ness, causality, severity and expectedness. Events that are 
considered serious, possibly, probably or definitely related 
to the IMP (serious adverse reactions) and unexpected 
(SUSAR) may be unblinded if it is necessary for clinical 
care. Once the investigator becomes aware that an SAE 
has occurred, they must report the information to the 
clinical research governance and quality assurance office 
of the sponsor within 24 hours. The investigator will then 
be required to complete an SAE form to assess causality, 
seriousness, severity and expectedness of the event.
AnAlysIs
statistical analysis
The principal analysis will be conducted on an intention-
to-treat basis. All analyses will allow for clustering by family, 
and all primary analyses will be adjusted for the minimis-
ation of variables. Comparisons will be performed using 
an appropriate linear modelling procedure, taking into 
account repeated measures where these are available. 
Patients with completely missing data for a particular 
outcome will be removed from the analysis of that partic-
ular outcome. The effect of this will be examined using 
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sensitivity analysis. Other sensitivity analyses will look at 
unadjusted analyses and the effect of adjusting for centre.
trial oversight
Monitoring will be performed in accordance with a study 
monitoring plan developed by the trial’s sponsor. The PIs 
and institutions involved in the study will permit trial-re-
lated monitoring, audits, research ethics committee review 
and regulatory inspection(s). A trial steering committee 
(TSC) will be established to oversee the conduct and 
progress of the trial. An independent data monitoring 
committee will be established to oversee the safety of 
subjects in the trial. The study is expected to provide new 
information on the evolution of PDB in this participant 
group as well to give an indication as to whether ZA treat-
ment can modify the natural history of the disease. Given 
the relatively short time frame it’s unlikely that the trial 
will demonstrate any clinical benefits of the treatment 
in terms of complications of PDB such as pain, fractures, 
deafness or bone deformity, but patients will be evaluated 
clinically for the presence of any of these complications 
should they occur.
Patient and public involvement
The study was designed with the involvement of patients 
and the Paget’s Association—a patient support group. 
The TSC included a representative of the Paget’s Associa-
tion and a patient representative.
EthICs And dIssEMInAtIOn
The results of the study will be submitted to a peer-re-
viewed journal so that they are disseminated to the wider 
medical community. The results will also be dissem-
inated to patients with PDB and their families through 
the website of the Paget’s Association. Authorship on 
the main paper will be determined by the International 
Committee of Medical Journal Editors guidelines. The 
results of the ZiPP trial are expected to inform clinical 
practice and influence clinical guidelines for PDB by 
determining if early intervention with ZA in presymptom-
atic individuals with SQSTM1 mutations can prevent or 
slow the development of bone lesions with an AE profile 
that is acceptable.
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